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Abstract
Background: Although poorly described in the literature, the practice of early (short-interval) rescreen after a
negative screening mammogram is controversial due to its financial and psychological burden and because it is of
no proven benefit.
Methods: The present study targeted an Italian 2-yearly screening programme (Emilia-Romagna Region, 1997-
2002). An electronic dataset of 647,876 eligible negative mammography records from 376,257 women aged 50-69
years was record-linked with the regional breast cancer registry. The statistical analysis addressed the following
research questions: (1) the prevalence of recommendation for early (<24 months) rescreen (RES) among negative
mammography reports; (2) factors associated with the likelihood of a women receiving RES; and (3) whether
women receiving RES and women receiving standard negative reports differed in terms of proportional incidence
of interval breast cancer, recall rate at the next rescreen, detection rate of breast cancer at the next rescreen and
the odds of having late-stage breast cancer during the interscreening interval and at the next rescreen.
Results: RES was used in eight out of 13 screening centres, where it was found in 4171 out of 313,320 negative
reports (average rate 1.33%; range 0.05%-4.33%). Reports with RES were more likely for women aged 50-59 years
versus older women (odds ratio (OR) 1.33; 95% CI 1.25-1.42), for the first versus subsequent screening rounds (OR
1.91; 95% CI 1.79-2.04) and with a centre-specific recall rate below the average of 6.2% (OR 1.41; 95% CI 1.32-1.50).
RES predicted a 3.51-fold (95% CI 0.94-9.29) greater proportional incidence of first-year interval cancers, a 1.90-fold
(95% CI 1.62-2.22) greater recall rate at the next screen, a 1.72-fold (95% CI 1.01-2.74) greater detection rate of
cancer at the next screen and a non-significantly decreased risk of late disease stage (OR 0.59; 95% CI 0.23-1.53).
Conclusion: The prevalence of RES was in line with the maximum standard level established by the Italian national
guidelines. RES identified a subset of women with greater incidence of interval cancers and greater prevalence of
cancers detected at the next screen.
Background
In breast screening, some negative mammography
reports recommend that women have their next mam-
mogram at a shorter time interval than the standard
one. Radiologists may advise an early rescreen for sev-
eral, not mutually exclusive, mammographic or patient-
reported conditions [1], including radiological
abnormalities of doubtful significance [2], the poor tech-
nical quality of mammograms [1], previous false-positive
results [3], initial versus a subsequent screen (that is,
the unavailability of previous mammograms for compar-
ison) [3], high levels of mammographic breast density
[1], premenopausal status [1], hormone replacement
therapy use [1], a family history of breast cancer [1-4],
previous breast cancer [2] including in situ carcinoma
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benign breast disease [4].
The objective of early rescreen, however, remains the
same for all women: to increase the sensitivity of screen-
ing for early-stage breast cancer. The earlier the repeat
screen, the higher the chance that a new or undetected
cancer will be picked-up by a mammogram during its
preclinical phase, rather than being diagnosed later as a
symptomatic interval cancer or as a late-stage cancer at
the standard 2-yearly rescreen.
Although this would seem to be an advantageous
option, the practice of early rescreen is controversial.
The arguments in favour are that early rescreen would:
(1) increase the likelihood of early detection in a subset
of women at a high risk of screening failure; (2) reduce
t h ev o l u m eo fm a l p r a c t i c el i t igation that results from
false-negative mammography findings; (3) limit the
recall rate (that is, the proportion of all women under-
going screening mammography who have an abnormal
result and are asked to come back immediately for an
additional imaging workup) at the initial screen; and (4)
avoid excessive increase in the recall rate when trained
radiological staff leave the programme because of turn-
over and are replaced by inexperienced personnel.
Arguments against early rescreen are that: (1) it has
been suggested [5] that it is a psychological burden; (2)
its benefits for women have not been demonstrated for
any condition [4], including radiological abnormalities of
doubtful significance; (3) an exhaustive rationale to
identify the expected outcome measures of early
rescreen has not been developed; (4) an experimental
evaluation of effectiveness is difficult to implement
within the current public health programmes; (5) the
reported or estimated rates of early rescreen vary from
as little as 1% in the UK [2] to as much as 10% or more
in Canada [3], suggesting that selection criteria are sub-
jectively interpreted; and (6) there is no estimate of
whether cost savings related to a decreased recall rate
outweigh the extra cost incurred by increased screening
frequency.
Given this uncertain background, it is understandable
that published practice guidelines and opinions are con-
flicting. Some experts think that the likelihood of breast
cancer for patients with radiological lesions of uncertain
clinical significance is high enough to warrant a full
diagnostic workup rather than a short-interval repeat
mammography [6]. Others, conversely, believe that the
criteria for early rescreen predict a risk of disease that is
unacceptably low [1]. The European guidelines for
breast screening suggest that intermediate mammo-
grams should not be performed [7]. Another view holds
that their number should be minimized [4] and that
further research is needed in order to assess whether,
and which, women with a negative mammogram should
be screened more often that every 2 years [3,4]. In Italy,
for example, the national guidelines have set an accepta-
ble standard of less than 1% of the screened population
[8].
It is quite plausible that inconsistencies and discrepan-
cies among guidelines have generated confusion in the
female public and also in the healthcare community.
However, this cannot be fully confirmed because the dif-
fusion and practice patterns of early rescreen in the
Western countries have been seldom investigated. To
the authors’ knowledge, only in Australia and Canada
are data on early rescreen regularly published as part of
statistical reports of screening activities [3,4]. In the
USA, the majority of published studies have dealt with a
subgroup of women - that is, those with ‘probably
benign’ mammographic abnormalities recommended for
short-interval mammography follow-up (American Col-
lege of Radiology Breast Imaging Reporting and Data
System (BI-RADS) category 3) [9-12]. It must be pointed
out that the conditions prompting early rescreen in Eur-
ope, which may also include high levels of mammo-
graphic breast density and non-radiological factors, are
not the equivalent of BI-RADS category 3 lesions. How-
ever, with the exception of a comprehensive survey of
the UK National Health Service screening centres pub-
lished several years ago [2], no study has ever been pub-
lished from any European screening programme.
This paper describes a study from a regional screening
programme in northern Italy. Our general objectives
were to evaluate the prevalence, the epidemiological
determinants and the possible outcomes of negative
mammography reports containing the recommendation
for early rescreen (abbreviated here as RES in partial
accordance with Ong et al. [2]).
Methods
Rationale and research questions
Between 1996 and 1998, as described in detail elsewhere
[13,14], a 2-yearly breast screening programme was
implemented for women aged 50-69 years living in the
Emilia-Romagna Region of northern Italy (n = 550,000).
We present an additional analysis of mammography
records collected for a previous investigation on the
proportional incidence of interval breast cancers [14].
The authors of the previous study found a subset of
negative results with RES (<24 months) which were
pooled with those not otherwise specified.
The rationale and objectives of our study were devel-
oped in a three-step process. First, since we found no
information on reasons for RES in the above mammo-
graphy records, we carried out a questionnaire-based
interview of the chief radiologists of the district screen-
ing units in order to determine which criteria had been
used, with whatever frequency, during 1997-2002. In
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vocal mammographic abnormality [2]; a high level of
breast density [1]; a strong family history of breast can-
cer [1-4]; a previously diagnosed atypical hyperplasia [4];
and a previously diagnosed breast cancer [2], including
in situ carcinoma [4], which referred to breast cancer
patients unknown to the screening service and, thus,
inadvertently invited.
Second, we established the study rationale. Our
approach was that the study endpoints (or the para-
meters of evaluation of RES) should include the
expected outcomes of RES from the radiologists’ view-
point. These were identified based on the following con-
siderations: the conditions identified from interviews are
risk factors for breast cancer; breast density [15,16],
family history [17] and previous breast cancer [18] are
also established risk factors for interval cancer; interval
and screen-detected cancers associated with a family
history have an increased growth rate [17]; and screen-
detected cancers preceded by a mammogram with find-
ings of uncertain clinical significance have a longer stay
in the preclinical detectable phase.
Due to these characteristics, women selected by radi-
ologists for early rescreen are expected to have a greater
incidence of interval cancer (over an interval of compar-
able length) and a greater detection rate of cancer on
the next screen than women scheduled for a 24-month
repeat mammogram. Without early rescreen, these
women would also have a greater proportion of late-
stage cancers detected either during the interscreening
interval or on the next rescreen. Shortening their inter-
screening interval aims precisely at increasing the likeli-
hood of a new or undetected breast cancer being
screen-detected by an early repeat mammogram during
its preclinical phase, rather than presenting later as a
symptomatic interval cancer or progressing to an
advanced stage before 24 months have elapsed. Based
on this rationale, we identified the two main endpoints
of the study: the prevalence of cancer among women
receiving RES; and the proportion of late-stage cancers
detected either during the interscreening interval or on
the next rescreen.
Third, and closely related to the above, the following
research questions were identified: (1) the prevalence of
RES among negative mammography reports; (2) factors
that are associated with the likelihood of a women
receiving RES; (3) whether women receiving RES and
women receiving standard negative reports differ in
terms of (a) proportional incidence of interval breast
cancer in the first and second interval year, (b) recall
rate at the next rescreen, (c) detection rate of breast
cancer at the next rescreen and (3) odds of having late-
stage breast cancer during the interscreening interval
and at the next rescreen.
Research design
The study design was: (1) to follow-up women starting
from the point when they had the first mammogram
meeting the following requirements - date 1997-2002,
woman’s age 50-69 years, invitation to screening, nega-
tive result with or without RES and unequivocal classifi-
cation as to the recommended time interval to next
screen; (2) to assess the incidence of first- and second-
year interval cancers during follow-up; and (3) to use
the pool of subsequent mammograms as the denomina-
tor for the detection rate. Subsequent mammograms
meeting the above requirements were used as a baseline
for another interscreening interval and, perhaps, another
rescreen.
Sample
As previously described [14], a dataset containing all the
nominative records from women undergoing mammo-
graphy between 1997 and 2002 was extracted from each
of the screening databases of the 13 regional health dis-
tricts. The datasets were sent to the study coordinating
centre in an encrypted format, checked for the confor-
mity of field properties, imported into the Stata software
(StataCorp LD, Texas, USA) and merged into a single
dataset. This new dataset was composed of 919,538
records from 495,294 women.
Definitions of interest
Specific methods were used in order to define and iden-
tify the negative and positive screening mammography
results as well as the interval and screen-detected can-
cers. In the dataset fields for the indication and result of
mammography, the attribute codes were decoded into
text descriptions using conversion tables provided by
each district screening unit. The final text descriptions
were grouped into broad types of indication (screening,
diagnostic assessment of a positive screening result, clin-
ical indication) and result (standard negative, negative
with RES, positive, unsatisfactory). For the following
three subsets of mammograms, the indication and/or
the result were defined using ap r i o r icriteria without
consideration of the original classification: (1) even
when recorded as screening tests, mammograms per-
formed within 24 months of a positive screening result
were assumed to have been performed for diagnostic
assessment; (2) by implication, early rescreen mammo-
grams were assumed to have been performed for screen-
ing, not diagnostic assessment; and (3) mammograms
reported as negative, but with the recommendation for
diagnostic assessment, were assumed to be positive.
Among the mammograms for which we retained the
original classification of indication and result, a mention
should be made of mammograms reported as negative
with RES, which we considered a subset of negative
results in accordance with Woodman et al.[ 1 9 ] ,a n do f
positive mammograms with negative diagnostic
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episode sensitivity’ [20,21] - that is, the combined ability
of mammography and of further assessments to identify
breast cancers in the screened population, which takes
into account the need for diagnostic confirmation after
a positive screening result - positive mammograms with
negative diagnostic assessment are reclassified as nega-
tive. Given our purposes, we did not use this approach
and restricted the definition of negative mammogram to
those which were originally reported as such.
As far as the detection mode of breast cancer is con-
cerned, we defined an interval breast cancer as an inva-
sive cancer clinically diagnosed within 24 months of an
eligible negative mammogram and before the date of the
first occurring censoring event (see Data analysis sec-
tion) [14]. This definition also applied to cancers diag-
nosed in lapsed attenders (women aged above 69 years
with previous eligible negative mammogram) [22] and
to cancers occurring in women whose last screening
result was negative and who declined subsequent invita-
tions [23].
For the purposes of this study, a screen-detected can-
cer was defined as an invasive cancer detected within 24
months of a positive rescreen mammogram.
Interval cancers and screen-detected cancers were
identified with record linkage of the mammography
dataset with the regional breast cancer registry [14].
Interval cancers were identified for the years 1997-2002.
In order to identify screen-detected cancers based on a
24-month follow-up of positive results, the mammogra-
phy dataset was record-linked with the registry files for
the years 1997-2004. Record linkage was done using the
first name, last name, date of birth, date of the last
mammogram and partial combinations of these vari-
ables. Manual checks of complete records in the origi-
nating databases were carried out for failed matches,
partial matches and multiple matches. The breast cancer
registry also provided tumour stage information.
Analysis
Prevalence of and factors associated with RES
Descriptive statistics and the c
2 test were used to ana-
l y z et h ep r e v a l e n c eo fR E Sin negative mammography
reports (research question No. 1). The independent fac-
tors associated with RES (research question No. 2) were
identified using a multiple logistic regression model.
Incidence of interval cancers
The incidence of interval breast cancers (research ques-
tion No. 3a) was expressed as a proportion of the
underlying incidence or proportional incidence. More
exactly, this is the ratio of the number of cancers occur-
ring in the interscreening interval to the number which
w o u l db ee x p e c t e di fs c r e e n i n gh a dn o tb e e no f f e r e d .
For both first and second interval year, women with a
negative mammography result were considered at risk of
interval cancer until the date of the next screen or the
365th day of interval or 31 December 2002, whichever
came first. The number of woman-years at risk was
adjusted for the risk of dying - that is, reduced by the
expected number of deaths based on the annual age-
specific (5-year groups) mortality rates from all causes
in the general female population. In order to determine
the expected number of cancers, the average age-specific
(5-year groups from 50 to 75 years) incidence rates for
the years 1991-1995 were applied to the appropriate
number of woman-years at risk. The ratio of observed:
expected ratios [24] and the 95% confidence interval
(CI) were used to compare the proportional incidence
observed after RES and that observed after standard
negative reports.
Recall rate
The recall rate observed at rescreen among women pre-
viously receiving RES and that observed among women
receiving a standard negative report were compared
(research question No. 3b) with the calculation of their
r a t i ow i t ht h e9 5 %C I .T h er a t i ow a sa d j u s t e db yt h e
woman’s age group.
Detection rate of cancer
The detection rate of breast cancer (research question
No. 3c) was expressed as the ratio of the number of
cancers detected within 2 years of positive mammo-
grams to the expected number based on the underlying
incidence or detected:expected ratio. The expected num-
ber was calculated by multiplying the average age-speci-
fic incidence rates for the years 1991-1995 by the
number of women undergoing rescreen. Women pre-
viously receiving RES and women receiving a standard
negative report were compared with the age-adjusted
ratio of detected:expected ratios and the 95% CI [24].
Odds of late-stage cancer
A late-stage breast cancer was defined as a lesion >20
mm in size (or pT2 or higher), or with lymph node
metastases or distant metastases. Small (pT1) cancers
not undergoing axillary surgery were classified as early-
stage cancers [25]. A multiple logistic regression model
was used to assess the odds ratio (OR) of late-stage ver-
sus early-stage disease for breast cancers (interval plus
screen-detected cancers) diagnosed among women pre-
viously receiving RES versus women scheduled for a
standard repeat screen (research question No. 3d).
Ethics
In accordance with the Italian legislation, no ethical
committee approval was sought. The study was an
observational one utilizing data obtained from a cancer
registry and a public health programme. Approval was
obtained from all institutions involved and from the
Department of Health of the Emilia-Romagna Region.
All personal identifiers were removed from the analysis
dataset.
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Prevalence of and factors associated with RES
The prevalence of RES was 0.64% of the total 647,876
eligible negative mammography reports from the entire
study area (Table 1). Restricting analysis to those centres
where negative reports with RES were used, the preva-
lence was 1.33%. RES was more common for younger
women, in the first screening round and in those centres
with lower recall rate. After inclusion in a multiple
logistic regression model (data not shown), these three
factors were confirmed to be independently associated
with RES. The OR was 1.33 (95% CI 1.25-1.42) for
women aged 50-59 years, 1.91 (95% CI 1.79-2.04) for
the first screening round and 1.41 (95% CI 1.32-1.50)
for a low recall rate. The recommended intervals to
early rescreen were distributed as follows: 12 months
73.8%; <12 months 16.6%; and >12 months 9.6%.
Incidence of interval cancers
During the first interval year, as shown in Table 2, the
proportional incidence of interval breast cancers
observed after RES was more than three times greater
than that observed after a standard negative result,
although the excess risk was of weak significance. Dur-
ing the second interval year (data not shown), the
cohort of women with a standard negative result accu-
mulated 198,949 woman-years and generated 172 inter-
val breast cancers. The proportional incidence was 0.36
(95% CI 0.31-0.42). Among women receiving RES (884
woman-years), 2.1 breast cancers were expected but
none was observed.
Recall rate
The number of negative mammography results which
were followed by a rescreen mammogram over the avail-
able observation time is shown in Table 3. The median
time to rescreen was 12 months (25th percentile, or
p25, 11 months; p75 14 months) for women receiving
RES and 25 months (p25 23 months; p75 28 months)
for women with standard negative results. The recall
rate for abnormal mammograms was 6.3% and 3.2%,
respectively. The ratio between these rates was 1.90
(95% CI 1.62-2.22).
Detection rate of cancer
Table 3 also shows the number of screen-detected
breast cancers and its ratio to the expected number,
which was 1.72-fold greater for women receiving RES.
Table 1 Prevalence of recommendation for early
rescreen.
Total screening centres (n = 13)
Women with at least one negative
mammography, n
376,257
Total negative mammographies, n 647,876
Negative mammographies with RES
n 4171
% 0.64
Screening centres using RES (n =8 )
Women with at least one negative
mammography, n
188,348
Total negative mammographies, n 313,320
Negative mammographies with RES
% 1.33
%, range between centres 0.05-4.33†
%, woman’s age 50-59 versus 60-69 years 1.51 versus
1.14‡
%, first versus subsequent screening rounds 2.15 versus
1.08‡
%, centres with recall rate <6.2% versus
≥6.2%*
1.63 versus
1.06‡
Table 2 Proportional incidence of first-year interval
breast cancers by type of previous negative
mammography report.
Mammography report
Standard
negative
Negative with
RES
Woman-years at risk, n* 272,710 3286
OBS, n (rate)† 96 (35.3) 4 (121.7)
EXP, n 640.4 7.6
OBS:EXP ratio (95% CI) 0.15 (0.12-0.18) 0.53 (0.14-1.35)
Ratio‡ of the OBS:EXP ratios
(95% CI)
1.00 (referent) 3.51 (0.94-9.29)
* Adjusted for general mortality and rounded to the whole-number value.
† Per 100,000 woman-years at risk.
‡ Adjusted for woman’s age (5-year groups).
RES, recommendation for early (<24 months) rescreen; OBS:EXP ratio,
observed:expected ratio or proportional incidence of interval cancers; CI,
confidence interval.
Table 3 Detection rate of breast cancer at the next
rescreen by type of previous negative mammography
report.
Mammography report
Standard
negative
Negative with
RES
Women at rescreen, n 127,936 2557
Abnormal results, n (%) 4125 (3.2) 161 (6.3)
DET, n (rate)* 539 (4.2) 18 (7.0)
EXP, n 304.5 5.9
DET:EXP ratio (95% CI) 1.77 (1.62-1.93) 3.04 (1.80-4.81)
Ratio† of the DET:EXP ratios
(95% CI)
1.00 (referent) 1.72 (1.01-2.74)
* Per 1000 women.
† Adjusted for woman’s age (5-year groups).
RES, recommendation for early (<24 months) rescreen; DET, detected (screen-
detected); DET:EXP ratio, ratio of screen-detected cancers to cancers expected
based on the underlying incidence; CI, confidence interval.
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The total number of breast cancers detected either during
the interscreening interval or at the next rescreen and the
proportion of late-stage cancers are shown in Table 4.
Women previously given RES had non-significant 40%
lower odds of late-stage breast cancer compared with
women who had had a standard negative report.
Discussion
Interpretation of results: prevalence of RES
There are few published data on the prevalence of RES,
especially from Europe, with which to compare our
results. Our finding of an average regional rate of 0.64%
negative reports with RES conforms with the Italian
national standard of no more than 1% [8]. In the UK
NHS Breast Screening Programme, the observed rate of
early rescreen in the same period of our study was 1.1%
[2]. In the USA, a rate of about 5% at first screen was
documented in large population studies [1,11], which
decreased to less than 2% at subsequent screens [11]. In
Canada, the estimated rate is above 10% [3].
Factors accounting for RES were not recorded in the
screening service databases. According to interviews
with radiologists, early rescreen was recommended on
the basis of mammographic findings (including abnorm-
alities of doubtful clinical significance and high levels of
breast density) and also several patient-reported condi-
tions. There are reasons, however, for assuming that
RES was generally due to mammographic findings. First,
one of the most common non-radiological factors for
RES -that is, a history of breast cancer- was virtually
absent from our data as women with this condition
were excluded from screening, with the exception of a
few who were inadvertently invited.
Second, inherent in the study design was the fact that
all interval cancers observed after RES arose within a
year of the negative mammography result. There are
sufficient data to indicate that early-presenting interval
cancers are mainly false-negative cancers for which, by
definition, a significant abnormality can be identified on
the original screening mammograms [26-28].
Third, as observed elsewhere [3,11], the prevalence of
RES decreased from the first to subsequent screening
rounds. This suggests that the lack of previous mammo-
grams with which to compare radiological abnormalities
of doubtful significance was a major factor for RES. The
age pattern of RES added further confirmation. While
the prevalence of breast cancer patients and of women
with a positive family history increases with age, the
prevalence of RES in our data showed the opposite
trend, consistent with the age prevalence of women with
high levels of breast density (possibly associated with
the use of hormone replacement therapy).
Another important factor associated with the preva-
lence of RES was the recall rate. Early rescreen was
more often recommended in screening centres where
the recall rate was lower than the regional average. In
other words, increasing the proportion of women given
RES was, as expected, a sort of compensation for a low
recall rate. In a previous work [14], it was suggested
that the relatively low incidence of interval breast can-
cers that is typical for Italian screening programmes
[29-31] cannot be properly interpreted without taking
into account their high average recall rate. Our data
show that the recall rate may also act as an inverse
determinant of the prevalence of RES.
Interpretation of results: occurrence of breast cancer
Negative mammography reports with RES identified a
cohort of women who were at greater risk of breast can-
cer than women scheduled for a standard 24-month
repeat mammogram, with a 3.51-fold increase in the
proportional incidence of first-year interval cancers
(there were no second-year cases because the accumula-
tion of follow-up time virtually ceased after 12 months),
and a 1.72-fold increase in the detected prevalence of
cancer at the next screen.
Although different, these two numbers indicate risk
increases of a similar magnitude. The odds for screen-
detected breast cancer increase with the increasing
interscreening interval. Based on previously published
data [14], the rate of onset of cancer in our cohort of
women approximately doubled in the second interval
year. As a consequence, a ratio of 1.72 between the
detected:expected ratios at 12 months is comparable
with a ratio of 3.51 at 24 months. Previous studies
[1,9,10,12] of women with BI-RADS category 3 lesions
have reported cumulative breast cancer rates of 0.5% [9]
to 2% [10], with follow-up periods varying from 6
months [12] to 3 years [9]. In the study by Yasmeen et
al. [1], the cumulative rate of breast cancer was about
twice that in women whose mammograms were
described as ‘benign’ and ‘negative’.H o w e v e r ,t h e r ea r e
several difficulties in comparing their data with ours.
Table 4 Odds ratio of late-stage disease for breast
cancers detected either during the interscreening
interval or at the next rescreen, by type of previous
negative mammography report.
Mammography report
Standard negative Negative with RES
Total cancers, n 807 22
Late-stage cancers
n 314 5
% 38.9 22.7
Odds ratio* (95% CI) 1.00 (referent) 0.59 (0.23-1.53)
* Adjusted for woman’s age (continuous).
RES, recommendation for early (<24 months) rescreen; CI, confidence interval.
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RES is not, or not merely, to select a subset of women
with greater prevalence of cancer. As some of the fac-
tors leading to RES identify women at increased risk of
late-stage cancer, the rationale of short-interval rescreen
is to shorten the preclinical detectable phase of new or
missed lesions. The ultimate objective of RES is to
detect these tumours before they progress to a more
advanced stage. In our small sample of cancers, women
previously given RES had non-significant 40% lower
odds of late-stage breast cancer compared with women
who had had a standard negative report. It can be con-
cluded that early rescreen achieved the objective of giv-
i n gt h e s ew o m e na tl e a s tt h es a m ec h a n c eo fe a r l y
detection as those receiving standard negative reports.
We have not found published data comparable to ours,
although there have been papers that have addressed
the favourable tumour stage [9] and the good prognosis
[6] of cancers detected among women with ‘probably
benign’ abnormalities recommended for short-interval
mammography follow-up.
Limitations in study design
A strength of the study design was the use of multiple
outcome measures, in particular the key assumption
that the ultimate medical objective of RES is to decrease
the odds of late-stage breast cancer both during the
interscreening interval and at the next rescreen.
Conversely, the comparison between RES and stan-
dard 2-yearly rescreen recommendation was retrospec-
tive and non-randomized, which may have introduced a
significant bias. The radiological and epidemiological
factors leading to RES are indications for more frequent
clinical surveillance between screens. Moreover, they
may stimulate women’s self-surveillance behaviour and
increase the perception of the risk and controllability of
breast cancer. Altogether, these effects may increase the
rate of interval cancers and favour their early, or timely,
detection. This is equivalent to saying that, for women
with high-risk conditions, there are factors other than
early rescreen that could favourably influence tumour
stage at diagnosis.
The ideal study design to assess the independent effec-
tiveness of RES would be a prospective, randomized trial
in which women diagnosed with (or reporting) those
conditions are randomly assigned to different interscre-
ening intervals. However, the feasibility of such a trial is
limited by the apparently small number of countries
where early rescreen is practised, the low prevalence of
eligible women, the expected contamination of all study
arms with frequent clinical surveillance and self-surveil-
lance and the likely presence of ethical concerns.
Nevertheless, future studies on this subject, whether
based on an experimental or observational retrospective
design, should enable us to improve our understanding
of some major aspects that warrant further investigation,
namely: the accuracy of case definition for women who
are candidate for early rescreen; the outcomes of early
rescreen as recommended for specific radiological and
epidemiological conditions; and the interactive or cumu-
lative effects of multiple exposures to these conditions.
Limitations in data quality
The present study also had limitations in data quality,
the most serious being the lack of recorded information
on factors accounting for RES, which was discussed ear-
lier. A second problem was that the electronic records
collected did not have a uniform format or coding.
However, with an empirical classification of mammo-
graphic codes coupled with checks of complete records
in the originating databases, we were able to evaluate as
many as 647,876 of the 655,175 negative records
included in the previous study of interval cancer inci-
dence [14]. Only 7299 (1%) were withdrawn from the
present analysis because of unclear information about
the interscreening interval recommended.
A third limitation potentially affecting our results lies
in the identification of patients with cancer. In Italy,
there is no universal identification number by which to
establish the identity of individuals and to link records
to them. In the present study, breast cancers were regis-
tered and classified for detection mode by the local can-
cer registries in collaboration with the district screening
units. After record linkage, the detection mode was
checked centrally against the mammography records.
Partial and failed matches were returned to the originat-
ing centre for further manual inquiries.
Further biases may have arisen from the methods used
to estimate the incidence of interval cancers. As far as
the observed incidence is concerned, a small number of
cancers occurring after a mammogram reported as
negative, but followed by diagnostic assessment [32],
was excluded from the definition of interval cancer.
Also excluded were those cancers observed after a posi-
tive mammogram with negative assessment which we
considered as interval cancers only for the estimate of
the screening episode sensitivity [21]. The expected
number of cancers was calculated using the incidence
rates observed in the last five pre-screening years,
although these rates were probably inflated by opportu-
nistic screening [33]. The method of linear extrapolation
of pre-screening incidence time trends to obtain the
underlying incidence in the screening years was not
used because it tends to amplify this bias [34].
Conclusions
Based on the above results, we see three reasons for not
discouraging the practice of early rescreen in the study
area: (1) the prevalence of RES is kept at a level that is
sustainable for the screening service; (2) our results on
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Page 7 of 9the determinants of RES suggest that decreasing the rate
of short-interval mammograms would translate into a
further increase in an already high recall rate for diag-
nostic assessment; and (3), despite potential biases and
limitations, our outcome results are at least suggestive
of a positive effect of RES on subsequent occurrence
and staging of breast cancer. However, as there are still
many open questions concerning the independent
effects and the optimal practice patterns of early
rescreen, we endorse the view that this practice should
be minimized [4] until further research establishes its
validity [3,4].
Abbreviations
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